Puranik, A.D.; Dromain, C.; Fleshner, N.; Sathekge, M.; Pavel, M.; Eberhardt, N.; Zengerling, F.; Marienfeld, R.; Grunert, M.; Prasad, V.
Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers 2021, 13, 3607.
https://doi.org/10.3390/cancers13143607
AMA Style
Puranik AD, Dromain C, Fleshner N, Sathekge M, Pavel M, Eberhardt N, Zengerling F, Marienfeld R, Grunert M, Prasad V.
Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers. 2021; 13(14):3607.
https://doi.org/10.3390/cancers13143607
Chicago/Turabian Style
Puranik, Ameya D, Clarisse Dromain, Neil Fleshner, Mike Sathekge, Marianne Pavel, Nina Eberhardt, Friedemann Zengerling, Ralf Marienfeld, Michael Grunert, and Vikas Prasad.
2021. "Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer" Cancers 13, no. 14: 3607.
https://doi.org/10.3390/cancers13143607
APA Style
Puranik, A. D., Dromain, C., Fleshner, N., Sathekge, M., Pavel, M., Eberhardt, N., Zengerling, F., Marienfeld, R., Grunert, M., & Prasad, V.
(2021). Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers, 13(14), 3607.
https://doi.org/10.3390/cancers13143607
